Related Experiment Video

Updated: May 22, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Neuropsychological measures predict decline to Alzheimer's dementia from mild cognitive impairment

Mathew J Summers1, Nichole L J Saunders

  • 1School of Psychology, University of Tasmania, Tasmania, Australia, and Wicking Dementia Research and Education Centre, Hobart, Tasmania, Australia. mathew.summers@utas.edu.au

Neuropsychology
|May 23, 2012
PubMed
Abstract

Insights

Mild Cognitive Impairment (MCI) outcomes vary significantly. Many individuals with MCI remain stable or improve, while a smaller percentage progress to dementia, highlighting the need for refined diagnostic criteria.

Area of Science:

  • Neuroscience
  • Gerontology
  • Cognitive Psychology

Background:

  • Mild Cognitive Impairment (MCI) is a transitional stage between normal aging and dementia.
  • Group-level studies show increased dementia conversion rates in MCI, but individual trajectories are highly variable.
  • Significant proportions of individuals with MCI may remain stable, change subtypes, or revert to normal cognition.

Purpose of the Study:

  • To investigate the 20-month individual outcomes of older adults classified by Mild Cognitive Impairment (MCI) subtypes.
  • To identify predictors of cognitive change and dementia progression within MCI subtypes.
  • To assess the stability and specificity of MCI subtype classifications over time.

Main Methods:

  • Longitudinal neuropsychological assessment of 106 older adults (81 with MCI subtypes, 25 controls) over 20 months.
  • Evaluation of visual and verbal memory, attention, executive functions, working memory, and semantic memory.
  • Discriminant function analysis to predict outcomes based on baseline cognitive performance.

Main Results:

  • At 20 months, 12.3% of the MCI group progressed to dementia, 62.9% remained MCI, and 24.7% reverted to normal cognition.
  • Baseline cognitive performance accurately predicted outcomes with 86.3% accuracy.
  • Impairments in episodic memory, working memory, and attention distinguished between progression, stability, and recovery.

Conclusions:

  • Existing MCI subtype criteria show considerable instability over time, questioning their specificity.
  • Multidomain MCI appears to be the most consistent predictor of progression to Alzheimer's Disease (AD).
  • Individualized outcome prediction requires comprehensive neuropsychological assessment beyond simple classification.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...